Financial reports
Current reports
6-K
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
14 Jun 24
6-K
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
11 Jun 24
6-K
Current report (foreign)
3 Jun 24
6-K/A
Current report (foreign) (amended)
17 May 24
6-K
Current report (foreign)
16 May 24
6-K
Molecular Partners Publishes Invitation to Annual General Meeting 2024
26 Mar 24
6-K
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
8 Jan 24
6-K
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
5 Jan 24
6-K
Current report (foreign)
11 Dec 23
6-K
Current report (foreign)
2 Nov 23
Registration and prospectus
S-8
Registration of securities for employees
28 Jun 23
F-3
Shelf registration (foreign)
1 Jul 22
424B4
Prospectus supplement with pricing info
16 Jun 21
F-1/A
Registration statement (foreign) (amended)
14 Jun 21
FWP
Free writing prospectus
14 Jun 21
8-A12B
Registration of securities on exchange
11 Jun 21
F-1/A
Registration statement (foreign) (amended)
10 Jun 21
F-6
Registration for ADRs (foreign)
9 Jun 21
F-1/A
Registration statement (foreign) (amended)
9 Jun 21
F-1/A
Registration statement (foreign) (amended)
12 May 21
Proxies
No filings
Other
EFFECT
Notice of effectiveness
13 Jul 22
EFFECT
Notice of effectiveness
16 Jun 21
EFFECT
Notice of effectiveness
16 Jun 21
SEC STAFF
SEC staff action: Order
16 Jun 21
CERT
Certification of approval for exchange listing
15 Jun 21
CORRESP
Correspondence with SEC
11 Jun 21
CORRESP
Correspondence with SEC
11 Jun 21
CORRESP
Correspondence with SEC
10 Jun 21
UPLOAD
Letter from SEC
9 Jun 21
CORRESP
Correspondence with SEC
12 May 21